1. Use of ß-blockers and mortality following ovarian cancer diagnosis: a population-based cohort study.
- Author
-
Johannesdottir SA, Schmidt M, Phillips G, Glaser R, Yang EV, Blumenfeld M, and Lemeshow S
- Subjects
- Adrenergic beta-Antagonists therapeutic use, Adult, Aged, Aged, 80 and over, Cohort Studies, Denmark epidemiology, Female, Humans, Middle Aged, Ovarian Neoplasms mortality, Proportional Hazards Models, Registries, Young Adult, Adrenergic beta-Antagonists adverse effects, Ovarian Neoplasms drug therapy
- Abstract
Background: Experimental data suggest that catecholamine hormones are involved in stimulating the aggressiveness of ovarian cancer, but few population-based studies have examined this association. We therefore conducted a population-based cohort study to examine whether ß-blockers affect mortality following ovarian cancer diagnosis., Methods: We used the Danish Cancer Registry to identify all patients diagnosed with ovarian cancer in northern Denmark between 1999 and 2010 (n=6,626). Data on medication use, comorbidity, and survival were obtained from medical databases. According to the last redeemed prescription before diagnosis, ß-blocker use was categorized as current (within ≤90 days), previous (>90 days) or never. We used Cox proportional hazards regression to calculate hazard ratios (HRs) for all-cause mortality with 95% confidence intervals (CIs) adjusting for confounding factors., Results: Among the ovarian cancer patients, 373 (5.6%) were current, 87 (1.3%) previous, and 6,166 (93.1%) were nonusers of ß-blockers. Median duration of use was 19.0 months among current users and 43.0 months among previous users. Median follow-up was 2.55 years (IQR: 0.81-9.23). Nonusers and current users of ß-blockers had similar comorbidity burden whereas previous users had moderate comorbidity more frequently. Compared with nonusers, the adjusted HR was 1.17 (95% CI: 1.02-1.34) for current users and 1.18 (95% CI: 0.90-1.55) for previous users. Secondary analyses stratifying by cancer stage and duration of ß-blocker use supported the overall results., Conclusions: We found no evidence that ß-blocker use was associated with decreased mortality following ovarian cancer diagnosis.
- Published
- 2013
- Full Text
- View/download PDF